Highest-materiality recent filing
Achieve Life Sciences shareholders approve doubling authorized common shares to 300M
Shareholders approved Certificate of Amendment increasing authorized common shares from 150M to 300M.
Achieve Life Sciences appoints Jeff Farrow and Dr. Reid Waldman to Board
Jeff Farrow appointed to Audit Committee as Chair and Nominating & Governance Committee as member.
Q1 cash $29.3M; closed $180M upfront financing; expects CRL by June 20, 2026; new CEO appointed
Q1 cash, equivalents, and marketable securities $29.3M; net loss $10.2M, operating expenses $10.5M.
Achieve Life Sciences raises $180M in private placement (up to $354M with warrants); CEO replaced
Gross proceeds of $180M upfront; warrants could add $174M if FDA approves cytisinicline for smoking cessation.
Achieve Life Sciences reports Q4/FY2025 net loss $54.7M; cytisinicline NDA PDUFA June 20, 2026
Cash $36.4M at Dec 31, 2025; net loss $14.7M Q4 and $54.7M FY2025.
ACHV Q3 net loss $14.4M; FDA accepts cytisinicline NDA, PDUFA June 20, 2026
Net loss $14.4M for Q3 2025; cash, equivalents & marketable securities $48.1M at Sep 30.
Dr. Jacobs resigned as Chief Medical Officer and President effective Oct 6, 2025.
Achieve Life Sciences CMO/President Cindy Jacobs resigns effective Oct 6, 2025
Dr. Cindy Jacobs resigned as Chief Medical Officer and President, effective October 6, 2025.
Achieve Life Sciences submits cytisinicline NDA to FDA; cash position $55.4M
NDA submitted to FDA in June 2025 for cytisinicline as smoking cessation treatment in adults.
Achieve Life Sciences prices $45M offering: 15M shares and warrants at $3.00 per unit
Public offering of 15M shares of common stock and accompanying warrants to purchase up to 15M shares, priced at $3.00 per unit.
Achieve Life Sciences shareholders reject director equity plan increase
All seven director nominees elected with majority 'for' votes; broker non-votes 11,422,484.
Q1 net loss $12.8M; on track for cytisinicline NDA submission to FDA in June 2025
Cash, equivalents, and marketable securities totaled $23.2M; operating expenses $12.9M for Q1 2025.
Achieve Life Sciences reports Q4 net loss $12.4M; reiterates cytisinicline NDA by end of Q2 2025
Cash, cash equivalents and marketable securities $34.4M as of Dec 31, 2024.
Achieve DSMC finds no safety concerns in ORCA-OL; NDA on track for Q2 2025
DSMC completed second independent review of ORCA-OL trial; no unexpected treatment-related adverse events identified.
Achieve Life Sciences appoints Nancy Phelan and Kristen Slaoui to board; Himes resigns
Dr. Vaughn Himes resigned from board effective Jan 6, 2025; no disagreement; will continue consulting.
Achieve Life Sciences appoints Mark K. Oki as CFO effective December 5, 2024
Mark Oki previously CFO of Aytu Biopharma, Vivus LLC, Alexza Pharmaceuticals.
Achieve Life Sciences Q3 net loss $12.5M; ORCA-OL enrollment complete, NDA on track for Q2 2025
Cash, equivalents and investments $42.9M as of Sep 30, 2024; operating expenses $12.5M for Q3.
Achieve Life Sciences enters $50M ATM equity offering with Jefferies for cytisinicline
Entered Open Market Sale Agreement with Jefferies for at-the-market offering of up to $50M of common stock.
CEO John Bencich departs; Richard Stewart named CEO, Thomas King Executive Chairman
John Bencich removed as CEO effective Aug 21, 2024; receives lump-sum severance of 18-month base salary and accelerated equity vesting.
Achieve Life Sciences Q2 net loss $8.5M; FDA Breakthrough Therapy for cytisinicline vaping cessation
Q2 net loss $8.5M vs $8.0M prior year; cash & equivalents $61.3M as of June 30, 2024.
Initial $10M term loan funded July 25, 2024; up to $10M additional subject to FDA NDA acceptance and lender approval.
Non-binding term sheet for up to $20M tranched facility from Silicon Valley Bank.
Achieve Life Sciences shareholders elect 8 directors, ratify PwC as auditor
All 8 director nominees elected with 14.1M–14.6M votes 'For'; broker non-votes of 10.2M.
Achieve Life Sciences reports Q1 net loss of $6.5M; cash $66.4M; ORCA-OL trial starts May 2024
Cash, cash equivalents, restricted cash $66.4M as of March 31, 2024, after $60M upfront financing.
Achieve Life Sciences reports 2023 net loss of $29.8M; FDA agrees on NDA path for cytisinicline
Net loss Q4 2023: $5.5M; full-year 2023 net loss: $29.8M; operating expenses $27.3M.
Achieve Life Sciences raises up to $124.2M in registered direct offering and private placement
$60M upfront from 13.09M shares at $4.585; warrants could add $64.2M at $4.906 exercise price.
Achieve Life Sciences: FDA requires long-term safety data; NDA filing likely delayed
FDA supports NDA on two Phase 3 trials but demands long-term safety data beyond 12 weeks for chronic-use label.
Achieve Life Sciences reports Q3 2023 net loss $7.1M; cash $20M; advances cytisinicline trials
Cash and restricted cash $20.0M as of Sep 30, 2023; net loss $7.1M in Q3 2023.
Achieve Life Sciences Q2 net loss $8.2M, cash $25.1M; advances cytisinicline NDA submission H1 2024
Net loss of $8.2M in Q2 2023; cash, equivalents and restricted cash $25.1M as of June 30, 2023.
Eight directors elected at June 7 annual meeting: Bencich, Duty, Himes, Jacobs, King, Martell, Sellig, Stewart.
Achieve Life Sciences prices $16.5M registered direct offering of 3M shares at $5.50/share
Sold 3,000,000 shares at $5.50 each for gross proceeds of ~$16.5M; net proceeds ~$15.2M.
12-week cytisinicline: 30.3% quit rate last 4 wks, 4.4x odds vs placebo (p<0.0001); continuous abstinence wk9-24: 20.5% vs 4.2%
Achieve Life Sciences enters $16.56M contingent convertible loan facility, refinancing prior debt
Term loan of $16.56M from Silicon Valley Bank/FCB and affiliates to refinance existing $15M contingent convertible debt.
Net loss of $9.0M for Q1 2023; cash, equivalents & restricted cash $16.6M as of March 31, 2023.
Achieve Life Sciences updates principal executive offices to two locations effective April 28, 2023
Effective April 28, 2023, Achieve Life Sciences established principal executive offices at 1040 West Georgia, Suite 1030, Vancouver, BC, Canada V6E 4H1.
Achieve Life Sciences appoints three new directors; three incumbents not standing for reelection
Stuart Duty, Thomas King, and Tom Sellig appointed to board effective March 29, 2023.
Amendment to March 1 Cooperation Agreement requires three new Board appointments by April 3, 2023.
Cash, cash equivalents, and restricted cash totaled $24.8M as of Dec 31, 2022.
Company to appoint three Designees to Board by March 21, 2023, filling vacancies from incumbent departures or board expansion.
Stockholders' equity as of Sept 30, 2022 was $1.0M, below Nasdaq's $2.5M minimum.
Achieve Life Sciences raises $18.9M in private placement of units at $4.625/unit
Gross proceeds of ~$18.9M from sale of 4,093,141 units at $4.625/unit; each unit consists of 2 common shares and a warrant to buy one share.
Achieve Life Sciences Q3 net loss $13.1M; Phase 3 ORCA-3 and Phase 2 ORCA-V1 enrollment completed
Net loss of $13.1M for Q3 2022; operating expenses $12.6M; cash and restricted cash $18.2M as of Sept 30, 2022.
Achieve Life Sciences Q2 net loss $10.5M; Phase 3 success and $2.5M NIH grant
Q2 2022 net loss of $10.5M; operating expenses $10.1M; cash & restricted cash $29.4M as of June 30.
All eight director nominees elected; votes ranged from 2,084,415 (Richard Stewart) to 2,226,016 (John Bencich) in favor.
Achieve reports Q1 net loss $7.6M; positive Phase 3 ORCA-2 cytisinicline results
Net loss of $7.6M for Q1 2022; cash & equivalents $36.4M as of March 31, 2022.
Primary endpoints met: 12-week cytisinicline had 32.6% abstinence vs 7.0% placebo (OR 6.3, p<0.0001); 6-week had 25.3% vs 4.4% (OR 8.0, p<0.0001).
Achieve Life Sciences appoints Vaughn Himes, PhD to Board of Directors
Dr. Himes appointed as director effective March 14, 2022; no committee assignment yet.
Achieve Life Sciences reports FY2021 net loss $33.2M; Phase 3 ORCA-2 topline data expected Q2 2022
Cash, cash equivalents and restricted cash of $43.1M as of Dec 31, 2021.
Achieve Life Sciences enters $15M contingent convertible debt agreement with SVB
$15M initial term loan from SVB and SVB Innovation Credit Fund VIII; up to $10M additional subject to approval.
Achieve Life Sciences Q3 net loss $6.7M; ORCA-2 topline data expected H1 2022
Cash equivalents $33.4M; total operating expenses $6.7M for Q3, $26.0M for 9 months.
the Board of Directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”) appointed Jeff Farrow and Reid Waldman, M.D. (together, the “Incoming Directors”), as directors, effective as of such date.
the Board of Directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”) appointed Jeff Farrow and Reid Waldman, M.D. (together, the “Incoming Directors”), as directors, effective as of such date.
Thomas King informed the Board that he has elected to resign from his position as a member and as chairman of the Board, effective as of June 8, 2026.
Jaime Xinos, the Company’s Chief Commercial Officer, will depart the Company, effective as of May 31, 2026.
Lucian Iancovici, MD, was appointed as Chair of the Board, effective as of June 8, 2026.
appointed Christopher Martin to serve as a director of the Company, effective immediately.
On January 6, 2025, the Board appointed each of Nancy R. Phelan and Kristen B. Slaoui, Ph.D. (together, the “Incoming Directors”) to serve as a director of the Company, effective January 6, 2025.
On January 6, 2025, Dr. Vaughn Himes informed the board of directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”), that he has elected to resign from his position as a member of the Board, effective immediately.
On January 6, 2025, the Board appointed each of Nancy R. Phelan and Kristen B. Slaoui, Ph.D. (together, the “Incoming Directors”) to serve as a director of the Company, effective January 6, 2025.
the Board of Directors of the Company (the “ Board ”) appointed Richard Stewart as the Company’s Chief Executive Officer, “principal executive officer” and “principal financial officer.”
determined that John Bencich will no longer serve as the Company’s Chief Executive Officer, “principal executive officer” or “principal financial officer,” effective as of August 21, 2024
Mr. Donald Joseph, Dr. Martin Mattingly and Mr. Jay Moyes (collectively, the “Outgoing Directors”), each a member of the Board, informed the Board that they would not be standing for reelection to the Board when their terms end at the Company’s 2023 annual meeting
Max materiality 0.90 · Median 0.65 · Most common event other_material